Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Commentary: Allograft Nerve Repair Reduces Postoperative Neuropathic Pain Following Nerve Biopsy
Wang, Huan , Spinner, Robert J.

Mayo Clinic

Neurosurgery | June 11, 2020 | Volume: 87 | Issue: 6 | Pages: E646-E647

10.1093/neuros/nyaa287 | PMID 32629468 Get It

Comparison of Echocardiographic parameters with Cardiac Magnetic Resonance Imaging in the Assessment of Right Ventricular Function
Chao, Chieh Ju, Siegel, Robert J. , Pujari, Sai Harika , Mookadam, Farouk, Venepally, Nithin R. , Wang, Panwen , Ashraf, Hasan , Marcotte, François , Semkiv, Oksana I., Fath, Ayman R. , Jokerst, Clinton, Agasthi, Pradyumna , Chao, Chieh‐Ju , Mookadam, Farouk , Ashraf, Hasan , Brown, Lisa Marie , Allam, Mohamed , Arsanjani, Reza

Mayo Clinic

No container title available | June 10, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.159183046.66745518 Get It

Introduction: The right ventricle (RV) strain measured by speckle tracking (RVS) is a novel method of assessing RV function. We compared RVS to RV fractional area change (FAC%), tricuspid annular peak systolic excursion (TAPSE) and Doppler tissue imaging-derived peak systolic velocity (S’) in the assessment of right ventricular (RV) systolic function measured using cardiac magnetic resonance imaging (MRI). Methods: We enrolled consecutive patients who underwent cardiac MRI between Jan 2012- Dec 2017 and a transthoracic echocardiogram (TTE) within 1 month of the MRI with no interval event. Baseline clinical characteristics and MRI parameters were extracted from chart review. Echocardiographic parameters were measured prospectively. TTE parameters including RVS, TAPSE, S’ and FAC% were tested for accuracy to identify impaired RV EF (EF <45% & <30%) using receiver operator curves. Results: The study cohort included 500 patients with mean age 55 yr ± 18 and right ventricular systolic pressure 33.7 ± 13.6 mmHg. The area under ROC for RVS was 0.69 (95% CI 0.63 – 0.75) and 0.78 (95% CI 0.70 – 0.88) to predict RVEF <45% & RVEF <30% respectively. The RV FAC % had second highest accuracy of predicting RVEF among all the TTE parameters tested in study. Conclusion: Right ventricular strain is the most accurate echocardiographic method to detect impaired right ventricular systolic function when using MRI as the gold standard.
A Multicenter Investigation Examining American Urological Association Recommended Antibiotic Prophylaxis vs Nonstandard Prophylaxis in Preventing Device Infections in Penile Prosthesis Surgery in Diabetic Patients
Towe, Maxwell , Osman, Mohamad M. , Huynh, Linda My , El‐Khatib, Farouk M. , Andrianne, Robert, Gross, Martin , Guise, Amy, Hatzichristodoulou, Georgios , Henry, Gerard D., Clavell-Hernández, Jonathan , Hsieh, Tung-Chin, Jenkins, Lawrence C. , Lentz, Aaron , Munarriz, Ricardo , Osmonov, Daniar , Park, Sung Hun , Perito, Paul , Sadeghi‐Nejad, Hossein , Sempels, Maxime, Simhan, Jay , Wang, Run , Yafi, Faysal A. , Broderick, Gregory, Jenkins, Lawrence , Rezaee, Michael E. , Broderick, Gregory A. , Burnett, Arthur L. “Bud” , Hsieh, Tung‐Chin

Mayo Clinic

Journal of Urology | June 10, 2020 | Volume: 204 | Issue: 5 | Pages: 969-975

10.1097/ju.0000000000001158 | PMID 32519913 Get It

Liver Cancer Immunity
Wang, Juan , El‐Khoueiry, Anthony B., Ilyas, Sumera I.

Mayo Clinic

Hepatology | June 9, 2020 | Volume: 73 | Issue: S1 | Pages: 86-103

10.1002/hep.31416 | PMID 32516437 Get It

Multicenter Study on the Diagnostic Performance of Native-T1 Cardiac Magnetic Resonance of Chronic Myocardial Infarctions at 3T
Wang, Guan , Yang, Qi , Sadras, Vignesh , Patel, Suraj , Yang, Hsin‐Jung , Sharif, Behzad , Kali, Avinash , Cokic, Ivan, Xie, Guoxi , Tighiouart, Mourad , Li, Debiao , Berman, Daniel S. , Chang, Hyuk‐Jae , Collins, Jeremy, Chang, Hyuk-Jae , Li, Debiao , Lee, Sang‐Eun , Collins, Jeremy D. , Dharmakumar, Rohan

Mayo Clinic

Circulation: Cardiovascular Imaging | June 8, 2020 | Volume: 13 | Issue: 6 | Pages: No page available

10.1161/circimaging.119.009894 | PMID 32507020 Get It

Background: Preclinical studies and pilot patient studies have shown that chronic infarctions can be detected and characterized from cardiac magnetic resonance without gadolinium-based contrast agents using native-T1 maps at 3T. We aimed to investigate the diagnostic capacity of this approach for characterizing chronic myocardial infarctions (MIs) in a multi-center setting. Methods: Patients with a prior MI (n=105) were recruited at 3 different medical centers and were imaged with native-T1 mapping and late gadolinium enhancement (LGE) at 3T. Infarct location, size, and transmurality were determined from native-T1 maps and LGE. Sensitivity, specificity, receiver-operating characteristic metrics, and inter- and intraobserver variabilities were assessed relative to LGE. Results: Across all subjects, T1 of MI territory was 1621±110 ms, and remote territory was 1225±75 ms. Sensitivity, specificity, and area under curve for detecting MI location based on native-T1 mapping relative to LGE were 88%, 92%, and 0.93, respectively. Native-T1 maps were not different for measuring infarct size (native-T1 maps: 12.1±7.5%; LGE: 11.8±7.2%, P =0.82) and were in agreement with LGE ( R 2 =0.92, bias, 0.09±2.6%). Corresponding inter- and intraobserver assessments were also highly correlated (interobserver: R 2 =0.90, bias, 0.18±2.4%; and intraobserver: R 2 =0.91, bias, 0.28±2.1%). Native T1 maps were not different for measuring MI transmurality (native-T1 maps: 49.1±15.8%; LGE: 47.2±19.0%, P =0.56) and showed agreement ( R 2 =0.71; bias, 1.32±10.2%). Corresponding inter- and intraobserver assessments were also in agreement (interobserver: R 2 =0.81, bias, 0.1±9.4%; and intraobserver: R 2 =0.91, bias, 0.28±2.1%, respectively). While the overall accuracy for detecting MI with native-T1 maps at 3T was high, logistic regression analysis showed that MI location was a prominent confounder. Conclusions: Native-T1 mapping can be used to image chronic MI with high degree of accuracy, and as such, it is a viable alternative for scar imaging in patients with chronic MI who are contraindicated for LGE. Technical advancements may be needed to overcome the imaging confounders that currently limit native-T1 mapping from reaching equivalent detection levels as LGE.
Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation
Norden, Pieter R. , Sabine, Amélie , Wang, Ying , Demir, Cansaran Saygili , Petrova, Tatiana V. , Kume, Tsutomu , Kume, Tsutomu , Wang, Ying , Liu, Ting

Mayo Clinic

eLife | June 8, 2020 | Volume: 9 | Issue: No issue available | Pages: No page available

10.7554/elife.53814 | PMID 32510325 Get It

Mutations in the transcription factor FOXC2 are predominately associated with lymphedema. Herein, we demonstrate a key role for related factor FOXC1, in addition to FOXC2, in regulating cytoskeletal activity in lymphatic valves. FOXC1 is induced by laminar, but not oscillatory, shear and inducible, endothelial-specific deletion impaired postnatal lymphatic valve maturation in mice. However, deletion of Foxc2 induced valve degeneration, which is exacerbated in Foxc1; Foxc2 mutants. FOXC1 knockdown (KD) in human lymphatic endothelial cells increased focal adhesions and actin stress fibers whereas FOXC2-KD increased focal adherens and disrupted cell junctions, mediated by increased ROCK activation. ROCK inhibition rescued cytoskeletal or junctional integrity changes induced by inactivation of FOXC1 and FOXC2 invitro and vivo respectively, but only ameliorated valve degeneration in Foxc2 mutants. These results identify both FOXC1 and FOXC2 as mediators of mechanotransduction in the postnatal lymphatic vasculature and posit cytoskeletal signaling as a therapeutic target in lymphatic pathologies.
P0680A POST-HOC ANALYSIS OF EFFICACY AND SAFETY OF TOLVAPTAN (TOL) IN DECREASING RATE OF RENAL FUNCTION DECLINE IN PATIENTS WITH VERY LATE-STAGE AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
Torres, Vicente, Gansevoort, Ronald T., Perrone, R. D., Chapman, Arlene B., Ouyang, John , Lee, Jennifer , Japes, Hina, Wang, Tao

Mayo Clinic

Nephrology Dialysis Transplantation | June 6, 2020 | Volume: 35 | Issue: Supplement_3 | Pages: No page available

10.1093/ndt/gfaa142.p0680 Get It

Abstract Background and Aims ADPKD is a progressive inherited disease that causes end-stage renal disease (ESRD) in ∼50% of the affected individuals by 60 years of age. TOL, a selective vasopressin V2-receptor antagonist, has been shown in randomized, placebo-controlled trials to slow the progression of renal function decline in ADPKD subjects with an eGFR of 25 mL/min/1.73m2 or higher. The efficacy and safety of TOL in subjects with lower eGFR remain understudied. This post-hoc analysis evaluated the efficacy and safety of TOL in subjects with stage 4 ADPKD (eGFR of &lt;30 mL/min/1.73m2). Method This is a retrospective analysis of a subgroup of ADPKD subjects who enrolled in the TOL long-term open-label extension (OLE) trial (NCT02251275). Included subjects had a baseline eGFR of &lt;30 mL/min/1.73m2, received ≥ 1 TOL dose, and were randomized to the placebo group in the REPRISE trial (NCT02160145). Two subgroups of subjects were analyzed, one with baseline eGFR of 25-30 (Subgroup 1) and one with &lt;25 (Subgroup 2). The variables evaluated included: 1) demographics, 2) adverse event (AE) profile, 3) intra-subject comparison of change in annualized eGFR decline during the open-label study (treatment period) to that during placebo use in the REPRISE trial (control period). Annualized eGFR change slopes in the treatment period were calculated using eGFR values between Month 1 and 12 visits to compensate for the acute hemodynamic effect of tolvaptan. Comparison was made by linear mixed model. Results Of the 1,803 subjects enrolled, 159 (8.8%) subjects (76 in Subgroup 1 and 83 in Subgroup 2) met the selection criteria for analysis. Annualized eGFR change slopes for all subjects (n=148) were -5.28 (SE 0.27) in the control period and -3.16 (SE 0.30) in the treatment period with a treatment effect of 2.11 mL/min/1.73m2/year (95% CI 1.56, 2.66), p&lt;0.0001). Demographic information, baseline eGFR, treatment duration and effects in the 2 subgroups are shown in the Table below. Treatment-emergent AEs were observed in 95% and 90% of the subjects in the 2 subgroups, respectively. Discontinuation due to AEs occurred in 15% and 17% of the 2 subgroups, respectively. The 5 most common AEs for all subjects were thirst (32%), polyuria (30%), renal pain (25%), blood creatinine increase (23%) and nocturia (22%); the rates were similar between the 2 subgroups. One incidence of hepatic enzyme increase, hemodialysis and death (unrelated to TOL) was observed in Subgroup 2, but not in Subgroup 1. Conclusion This post-hoc analysis demonstrated that TOL significantly decreases the rate of eGFR decline in ADPKD subjects with stage 4 CKD, including those with an eGFR of &lt;25 mL/min/1.73m2.
Inverted Papilloma of the Orbit and Nasolacrimal System
Wang, Jessie , Ford, Joshua , Esmaeli, Bita , Langer, Paul D. , Esmaili, Neda, Griepentrog, Gregory J. , Couch, Steven M., Nguyen, John , Gold, Katherine G., Duerksen, Kathleen M., Burkat, Cat N., Hartstein, Morris E., Gandhi, Parag, Sobel, Rachel K. , Moon, Jee‐Young , Barmettler, Anne

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | June 5, 2020 | Volume: 37 | Issue: 2 | Pages: 161-167

10.1097/iop.0000000000001719 | PMID 32501879 Get It

Purpose: Periocular inverted papilloma (IP) is a rare, locally aggressive tumor with a propensity for recurrence and malignant transformation. Historically treated via wide excision, this study examines the characteristics and management of periocular IP, comparing those confined to the nasolacrimal system with those invading the orbit. Methods: An Institutional Review Board-approved, Health Insurance Portability and Accountability Act-compliant retrospective, comparative case series was conducted in patients with IP of the orbit or nasolacrimal system across 15 clinical sites. Results: Of 25 patients, 22 met inclusion criteria with 9 limited to the nasolacrimal system and 13 invading the orbit. Mean age was 60.4 years, 55% were women, all were unilateral. Mean follow-up was 48 months. Rates of smoking, dust and/or aerosol exposure, human papillomavirus (HPV) status, and inflammatory polyps were elevated compared to rates in the general population (45%, 18%, 18%, and 14%, respectively). Bony erosion on computed tomography scans was statistically significantly associated with orbit-invading IP (p = 0.002). Treatment involved all confined IP undergoing surgery alone while 39% of orbit-invading IP also received radiation therapy and/or chemotherapy (p = 0.054). Orbit-invading IP was more likely to be excised with wide margins than IP confined to the nasolacrimal system (85% vs. 22%, p = 0.007). Overall rates of malignancy, recurrence, and patient mortality from IP were found to be 27%, 23%, and 9%, respectively. Conclusions: IP invading the orbit typically requires aggressive therapy, while IP confined to the nasolacrimal system may be treated more conservatively. Using risk factors, characteristics, and outcomes, a treatment algorithm was created to guide management.
Study Design and Rationale of EXPLORER-HCM
Ho, Carolyn Y. , Olivotto, Iacopo , Lester, Steven J., Roe, Matthew T. , Wang, Andrew , Waldman, Cynthia Burstein, Sehnert, Amy J. , Olivotto, Iacopo , Wang, Andrew , Ho, Carolyn Y , Jacoby, Daniel Louis , Zhang, David, Heitner, Stephen B.

Mayo Clinic

Circulation: Heart Failure | June 5, 2020 | Volume: 13 | Issue: 6 | Pages: No page available

10.1161/circheartfailure.120.006853 | PMID 32498620 Get It

Background: Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by unexplained left ventricular (LV) hypertrophy associated with dynamic LV outflow tract obstruction. Current medical therapies are nonspecific and have limited efficacy in relieving symptoms. Mavacamten is a first-in-class targeted inhibitor of cardiac myosin, which has been shown to reduce LV outflow tract obstruction, improve exercise capacity, and relieve symptoms of oHCM in the PIONEER-HCM phase 2 study. Methods: EXPLORER-HCM is a multicenter, phase 3, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of mavacamten in treating symptomatic oHCM. Eligible adults with oHCM and New York Heart Association Functional Class II or III are randomized 1:1 to receive once-daily, oral mavacamten, or matching placebo for 30 weeks. The primary composite functional end point is clinical response at week 30 compared to baseline defined as either (1) an increase in peak oxygen consumption ≥1.5 mL/kg/min and reduction of at least one New York Heart Association class; or (2) an improvement of ≥3.0 mL/kg/min in peak oxygen consumption with no worsening of New York Heart Association class. Secondary end points include change in postexercise LV outflow tract gradient, New York Heart Association class, peak oxygen consumption, and patient-reported outcomes assessed by the Kansas City Cardiomyopathy Questionnaire and a novel HCM-specific instrument. Exploratory end points aim to characterize the effect of mavacamten on multiple aspects of oHCM pathophysiology. Conclusions: EXPLORER-HCM is a phase 3 trial in oHCM testing a first-in-class, targeted strategy of myosin inhibition to improve symptom burden and exercise capacity through reducing LV outflow tract obstruction. Results of this trial will provide evidence to support the first disease-specific treatment for HCM. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03470545.
STK38 promotes ATM activation by acting as a reader of histone H4 ufmylation
Qin, Bo , Yu, Jia , Nowsheen, Somaira , Wang, Liewei , Lou, Zhenkun , Lou, Zhenkun , Zhao, Fei

Mayo Clinic

Science Advances | June 3, 2020 | Volume: 6 | Issue: 23 | Pages: No page available

10.1126/sciadv.aax8214 | PMID 32537488 Get It

STK38, a reader of histone H4 ufmylation, regulates ATM activation.